While the drug is already authorized by the Food and Drug Administration for emergency use in mild to moderate cases of COVID-19, Regeneron is seeking approval for the drug to be administered to treat more severe cases. "Regeneron is in discussions with the FDA to expand the current Emergency Use Authorization to other populations, including the prevention and hospitalized patient settings," the company announced in their statement. If approved, the drug would be the first antibody treatment to be authorized for treating severe cases of COVID-19, according to The Wall Street Journal.